Earnings Scheduled For April 9, 2024
Companies Reporting Before The Bell
• Tilray Brands (NASDAQ:TLRY) is projected to report quarterly loss at $0.05 per share on revenue of $198.62 million.
NeurAxis, Inc. Issues Letter To Shareholders From Brian Carrico, President And Chief Executive Officer
NeurAxis, Inc. (NYSE American: NRXS) ("NeurAxis" or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults,
NeurAxis Signs Exclusive Option Agreement With University Of Michigan For Innovative Gastrointestinal Device
NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced it
NeurAxis Announces Results Of Comparative Study Of IB-Stim And Standard Medical Therapy In Adolescents With Functional Abdominal Pain Disorders
NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced
Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session
Tenon Medical, Inc. (NASDAQ: TNON) shares climbed 63.5% to $0.2351 after the company announced it has withdrawn its proposed public offering of shares of its common stock.
EXCLUSIVE: NeurAxis’ Nerve Field Stimulation Tech Shows Improved Quality of Life of Adolescents Patients With Irritable Bowel Syndrome
NeurAxis Inc (NYSE: NRXS) announced the publication of a Prospective study evaluating the efficacy of IB-Stim in children featured in the September 2023 Frontiers in Pain Research.
EXCLUSIVE: Small MedTech Firm NeurAxis Targets $2B Market With Post-Concussion Therapy In Kids
NeurAxis Inc (NYSE: NRXS) highlighted A Prospective Study on the Effect of Auricular Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients with Post-Concussion Syndrome (PCS), a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of IB-Stim in children with post-conc
NeurAxis Announces Over $8M In IB-Stim Revenue
NeurAxis, Inc. (NYSE American: NRXS) ("NeurAxis" or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in
NeurAxis Announces Pricing Of $6.592M Initial Public Offering Of 1,098,667 Shares Of Common Stock At An Price Of $6/Share
NeurAxis, Inc. (NYSE American: NRXS) ("NeurAxis" or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in